Linksys Launches Hydra Pro 6, the Newest Addition to its Lineup of WiFi 6 Routers
4.1.2022 19:00:00 EET | Business Wire | Press release
Linksys, a global leader in home and business WiFi solutions, today announces the availability of its latest and more affordable WiFi 6 product, the Hydra Pro 6.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220104005357/en/
Linksys Hydra Pro 6 (Photo: Business Wire)
“Our mission at Linksys is to connect everyone securely, whether it’s someone working from home who needs reliable WiFi or a student intently taking notes during their online class. The Hydra Pro 6 is our latest router in a suite of products that offer next-level streaming, are easy to set up and equipped with advanced security and parental controls,” said Harry Dewhirst, CEO, Linksys. “People shouldn’t worry about a dropped video chat or connections that aren’t secure. WiFi is meant to make life easier not create unnecessary problems in an already difficult world. We are committed to delivering fast, reliable, and secure connectivity to the hybrid work era and beyond, and the Hydra Pro 6 is just the start.”
The Linksys Hydra Pro 6 delivers the ultimate WiFi 6 experience to 30+ devices (per node) across 2700 sq. ft. of coverage and wireless speeds up to 5.4 Gbps. Powered by the Qualcomm® Immersive Home 216 Platform plus access to 160 MHz channel, the Hydra Pro 6 unleashes the true power of WiFi 6 with reliable, incredibly fast connectivity and improved network efficiency for seamless video streaming, faster downloading and more. Intelligent Mesh technology offers whole home mesh WiFi coverage that’s easily expandable by adding nodes.
At a time when device-heavy homes are more dependent on WiFi than ever before, the powerful yet easy to use Hydra Pro 6 is a seamless addition to households and allows users to view/prioritize devices through the free Linksys app. Additional features include WPA3/WPA2-Personal encryption and SPI firewall, automatic security updates, parental controls, and a separate guest network.
The Linksys Hydra Pro 6 is available now in the U.S. for $299 on Linksys.com and is coming soon to major retailers across the globe. For more information on the product please visit: https://www.linksys.com/us/p/p-mr5500/
Product imagery can be found here.
About Linksys
At Linksys, we strive to build the world’s most reliable, innovative, future-ready wireless technologies that can securely connect every person and everything, effortlessly. Founded in 1988, Linksys has since established itself as a premier networking brand. Today, Linksys hardware products, software, and services are sold in 64 countries worldwide, ranging from home routers and mesh systems to business access points and switches. Recently, Linksys expanded into education and enterprise through its partnership with Fortinet, the leader in enterprise-grade security. Linksys. For every connection.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm Immersive Home Platform is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005357/en/
Contact information
Asees Singh
Sr. Global Communications Manager
Comms@linksys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom